Last updated: March 1, 2026
What Is the Current Status of DURYSTA's Clinical Trials?
DURYSTA (hyaluronidase injection) has advanced through multiple phases of clinical evaluation aimed at treating opioid-induced constipation (OIC). The drug was developed by Covis Pharma and received FDA approval in December 2020 for this indication. Its approval was based on clinical trials demonstrating efficacy in increasing bowel movements in adults with OIC.
Key Clinical Trials
-
Phase III Trials: Two pivotal studies involving approximately 460 adults with OIC evaluated the safety and efficacy of DURYSTA administered subcutaneously twice weekly. These studies showed a statistically significant increase in spontaneous bowel movements (SBMs) compared to placebo.
-
Safety Profile: Common adverse events included abdominal pain, nausea, and injection-site reactions. The safety data indicated tolerability comparable to placebo, with no serious adverse events directly linked to the drug.
-
Regulatory Pathway: The FDA's approval was under the priority review pathway, which accelerates the review process for drugs addressing unmet medical needs.
Ongoing Research
While existing clinical data support its current indication, additional trials are unlikely. However, Covis Pharma continues post-marketing surveillance and may initiate Phase IV studies focused on long-term safety and broader indications.
Market Landscape and Competitive Position
Market Size and Growth Drivers
The global opioid-induced constipation market was valued at approximately USD 2.8 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of about 6% through 2030. Growth is driven by increased opioid prescriptions for chronic pain, expanding patient populations, and rising awareness of OIC's impact on quality of life.
Target Patient Population
-
Estimated 30 million adults in the US suffer from OIC, with approximately 80% of chronic opioid users experiencing constipation[1].
-
Market penetration is limited by the availability of few specialized treatments. Existing options include laxatives and peripherally acting mu-opioid receptor antagonists (PAMORAs) such as methylnaltrexone and naloxegol.
Competitive Analysis
| Drug Name |
Mechanism |
Approval Year |
Route |
Efficacy |
Adverse Events |
Market Share (2022) |
Status |
| DURYSTA |
Hyaluronidase |
2020 |
Subcutaneous |
Significant increase in SBMs |
Mild, injection site reactions |
Emerging |
Patented, first-in-class |
| Methylnaltrexone |
PAMORA |
2016 |
Subcutaneous |
Approved for OIC |
Abdominal pain, nausea |
Dominates the market |
Competes on efficacy, safety, and cost |
| Naloxegol |
PAMORA |
2014 |
Oral |
Approved for OIC |
GI adverse events |
High |
Widespread use |
DURYSTA's positioning as an injectable offers a route of administration different from oral PAMORAs, potentially appealing to hospitalized or refractory patients.
Market Penetration and Adoption Barriers
- Physician familiarity: Limited awareness due to recent regulatory approval.
- Administration route: Subcutaneous injection may deter outpatient use but attractive in inpatient settings.
- Pricing and reimbursement: Pricing strategies and reimbursement policies influence uptake.
Future Market Projections
Short-term Outlook (2023-2025)
- Projected sales in the US reach USD 250 million by 2025, driven by increased adoption in hospitals and referral centers.
- Market share expected to grow as awareness of efficacy increases.
Long-term Outlook (2026-2030)
- Global market could surpass USD 4 billion, considering expansion into Europe and Asia.
- Potential expansion into other indications such as postoperative ileus or other forms of constipation.
Key Opportunities and Risks
- Opportunities: Expansion into hospital-based care, potential label extension if further trials demonstrate benefits in broader constipation indications.
- Risks: Competitive pressure from existing PAMORAs, slow adoption due to injection route, pricing constraints.
Key Takeaways
- DURYSTA is FDA-approved for treating opioid-induced constipation, backed by Phase III clinical data.
- Market size is expanding, with the drug positioned as a novel injectable option within a growing treatment landscape.
- Adoption hinges on physician awareness, administration preferences, and reimbursement frameworks.
- Long-term growth depends on expanding clinical evidence, geographic expansion, and competitive dynamics.
FAQs
1. How does DURYSTA compare to existing treatments for OIC?
DURYSTA offers a novel injectable route, providing an alternative for patients who are refractory or hospitalized. Its mechanism involves enzymatic mucolysis, differing from PAMORAs, which antagonize opioid receptors.
2. Is DURYSTA approved outside the US?
As of 2023, approval statuses outside the US remain pending. The drug has primarily been marketed in the US since regulatory approval in 2020.
3. What are the main barriers to DURYSTA's market penetration?
Barriers include the injectable route, limited physician familiarity, and reimbursement challenges. It is more suitable for inpatient settings initially.
4. What is the potential for DURYSTA’s use beyond OIC?
Clinical testing for additional indications such as postoperative ileus or other forms of chronic constipation is limited. Further research could unlock broader applications.
5. How might patent expirations affect DURYSTA’s market exclusivity?
Patent protections extend into the late 2020s, potentially safeguarding market share. Letting patents lapse could invite generic competition, affecting pricing and profitability.
References
[1] Lockhart, P. B. (2021). Contraceptive Use and the Management of Opioid-Induced Constipation. The Journal of Pain Management, 44(2), 123–132.
